Posted by Michael Wonder on 05 Jul 2021
Diurnal receives marketing authorisation for Efmody in Great Britain from the MHRA
2 July 2021 - Efmody provides a new treatment option for c.5,000 patients suffering from congenital adrenal hyperplasia in Great Britain.
Diurnal Group announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorisation for Efmody (hydrocortisone modified-release hard capsules – development name Chronocort) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia.
The Marketing Authorisation for Efmody from the MHRA applies in Great Britain (England, Wales and Scotland) and follows the recent approval of the product in the European Economic Area (including Northern Ireland) by the European Commission as announced on 28 May 2021.
